Verastem plans IPO this week
January 23rd, 2012
No comments
Verastem is scheduled to launch an initial public offering (IPO) … this week. Read more…
Archive
Archive for the ‘Financing’ Category
ImmunoCellular Therapeutics (OTC BB: IMUC) prices $9.4M Unit Offering
January 10th, 2012
No comments
OTCBB: IMUC priced an offering of 9,489,436 units, Read more…
Categories: Financing, ImmunoCellular Therapeutics, IMUC.OB
Verastem files for $50M IPO
November 3rd, 2011
No comments
Verastem filed intentions for an initial public offering (IPO) of stock that could raise up to $50M . Read more…
TiGenix (NYSE Euronext: TIG) Financing facility for P3 Crohn’s disease Trial
October 3rd, 2011
No comments
TIG’s wholly-owned subsidiary Cellerix SA is to receive a EUR 4.95M soft loan from the “Madrid Network” to Read more…
Categories: Financing, TiGenix (TIG) combination with Cellerix
Pluristem (PSTI) files Shelf to raise $150M
September 27th, 2011
No comments
NASDAQ: PSTI; DAX: PJT: PLTR has filed a shelf prospectus with the US SEC to raise up to $150M in shares, preferred shares, and warrants. Read more…
Categories: Financing, NASDAQ: PSTI, Pluristem Therapeutics
BioTime’s (AMEX: BTX) OncoCyte expands programs with $10M Equity Financing
August 24th, 2011
No comments
Expanding Cancer Programs Read more…
Categories: AMEX: BTX, BioTime (AMEX:BTX), Financing
Hamilton Thorne (TSV-V: HTL) $3M Private Placement
August 9th, 2011
No comments
Hamilton Thorne Ltd. (TSX-V: HTL) is proposing to issue a private placement of an aggregate of approximately 12M common shares Read more…
Categories: Financing, Hamilton Thorne Ltd. (TSX-V: HTL)
Cevec Raises $8.5M to Commercialize Human Cell-Expression Platform for producing Proteins and Vaccines
July 28th, 2011
No comments
Firm aims to exploit human amniocyte-derived cell lines through new vaccine development partnerships Read more…
Categories: Cevec Pharmaceuticals, Financing
Cardio3 BioSciences seeks 20M Euros in funding for Stem-Cell Trials
July 27th, 2011
No comments
Cardio3 BioSciences, the maker of an experimental stem-cell heart therapy called C-Cure is …. (hoping) raising Read more…
Categories: Cardio3 BioSciences, Financing
NeoStem (Amex: NBS) Public Offering of Common Stock
July 19th, 2011
No comments
NYSE-Amex: NBS to sell shares of its common stock and warrants in a public offering. Read more…
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.